Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amgen, Xencor to tie up for monoclonal antibody development
As per the terms of the agreement, Amgen has the option for the exclusive worldwide license of XmAb 5871 following the completion of a pre-defined Phase 2 study.
As per the terms of the agreement, Amgen has the option for the exclusive worldwide license of XmAb 5871 following the completion of a pre-defined Phase 2 study.
The joint venture CRO is based in Bangkok and is expected to conduct clinical research in key South East Asian countries under the name Ecron Acunova Company (EACL)
Skainar AL tablets contain azelastine hydrochloride as an active ingredient to inhibit the excessive production and release of histamine and leukotriene, two chemicals responsible for causing allergic symptoms.
The multi-dose, single-arm, multi-centre, open-label, dose-escalation Phase I study is designed to define the toxicity profile, maximum tolerated dose, immunogenicity, pharmacokinetics, and potential anti-tumour activity of MGAH22. The
As per the agreement, Spirogen will take the responsibility to manufacture and synthesize drug reagents to generate ADCs and investigate their potential therapeutic utility. Genentech will have the
Virdante has exclusively licensed the Sialic Switch technology from The Rockefeller University and established a strategic research alliance with Jeffrey Ravetch laboratory. The new US patent covers the
InSite Vision‘s Phase 1/2 study is designed to evaluate the safety and efficacy of ISV-303 when administered either once or twice daily. In the trial, the patients were
The patent assigned to Odyssey Thera, further protects assays utilizing fragments of inherently fluorescent proteins, and the use of the assays for screening of defined panels of proteins.
ALD-401 is the population of stem cells produced using Aldagen’s proprietary technology to sort a specified quantity of bone marrow collected from the patient receiving the therapy. Preclinical
Omeros claims that its proprietary antifibrinolytic agents are highly selective inhibitors of plasmin, the enzyme responsible for fibrinolysis and dissolving blood clots, while avoiding inhibition of Factor XIa